Pre-Made Dalantercept biosimilar, Fusion Protein: Recombinant therapeutic protein targeting BMP10 fused with human IGHG1 Fc (Fragment constant) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
ALK inhibitors are anti-cancer drugs that act on tumours with variations of anaplastic lymphoma kinase (ALK) such as an EML4-ALK translocation. They fall under the category of tyrosine kinase inhibitors, which work by inhibiting proteins involved in the abnormal growth of tumour cells. All the current approved ALK inhibitors function by binding to the ATP pocket of the abnormal ALK protein, blocking its access to energy and deactivating it.
A majority of ALK-rearranged NSCLC harbour the EML4-ALK fusion, although as of 22, over 92 fusion partners have been discovered in ALK+ NSCLC. For each fusion partner, there can be several fusion variants depending on the position the two genes were fused at, and this may have implications on the response of the tumour and prognosis of the patient.
Dalantercept is a fully-human, recombinant fusion protein produced by linking the extracellular domain of the human ALK1 receptor to the Fc portion of human immunoglobulin G1 (ALK1-Fc) that binds BMP9 and BMP10 with high affinity and acts as a ligand trap. Activin receptor-like kinase 1 (ALK1) is a type I receptor of the transforming growth factor beta (TGF-¦Â) superfamily that is selectively expressed on the surface of activated endothelial cells and binds with high affinity to its ligands bone morphogenetic proteins (BMPs) 9 and 10. ALK1 and BMP9 may have functional relevance not only in tumor angiogenesis but also in tumor metastases. blocking Activin receptor-like kinase 1 (ALK1) might enhance the efficacy of vascular endothelial growth factor inhibition in renal cell carcinoma.